(1) A serum sample for diphtheria toxoid antibodies was negative on day 7.

(2) I want 0 . 5 cc. of tetanus toxoid.

(3) Toxoid booster injections are recommended.

(4) A booster dose of tetanus and diphtheria toxoid–containing vaccine should be given to adults who completed a primary series 10 or more years previously.

(5) Therefore, using toxoid to make preventive inoculation can avoid spread of this infectious disease.

(6) The delayed hypersensitivity induced by the diphtheria toxoid with different purity and dose was investigated to guide the vaccine production and improve the vaccine quality.

(7) OBJECTIVE To investigate the stability of microencapsulated tetanus toxoid in the courses of preparation and release, and improve its stability by co encapsulation of additives.

(8) Immunization of women of childbearing age with tetanus toxoid (TT) vaccine has for many years been an integral part of national immunization programmes in developing countries.

(9) Finally the immunogenicity of tetanus toxoid encapsulated in the microspheres was evaluated.

(10) Widespread use of this modified toxoid began in the 1940s when it was combined with the tetanus and pertussis vaccines.

(11) A booster does of tetanus toxoid and penicillin should be administered.

(12) All the 14 immunized rabbits with paraoxon-tetanus toxoid survived after a challenge of 1LD of paraoxon injected intramuscularly .

(13) AIM To evaluate the immunogenicity of tetanus toxoid (TT) encapsulated in biodegradable polymer microspheres composed of polylactide (PLA).

(14) Objective: To study on in vitro release of tetanus toxoid contained in polylactide microspheres and the influence of additives on the drug release.

(15) Among the 7 artificial paraoxon antigens studied, we found that paraoxon-tetanus toxoid has the best immunologic effect.

(16) Authorities confessed that diphtheria may occur in vaccinated individuals, and noted that "the permanence of immunity induced by the toxoid...is open to question."

(17) In 1975, the Food and Drug Administration (FDA) concluded that diphtheria toxoid "is not as effective an immunizing agent as might be anticipated."

(18) Objective To study the influence of length of polysaccharide(PS)fragment on the immunogenicity of Streptococcus pneumoniae type 18C polysaccharide(Pn18C)-tetanus toxoid(TT)conjugate.

(19) Methods Conjugate was prepared by carbodiimide mediated coupling of adipic acid hydrazide derivatives of capsular polysaccharides of group A meningococcal with tetanus toxoid(TT).

(20) This article presents the results of standardization of adsorbed purified tetanus toxoid by 3 potency test methods.

(21) Objective To compare the antibody responses induced with Streptococcus pneumoniae capsular polysaccharide-tetanus toxoid (TT) conjugates by two immune routes in mice.

(22) Tetanus is a severe spastic disease caused by tetanus toxin, which can be prevented by immunization with tetanus toxoid.